IL122650A0 - Azetidinone derivatives for the treatment of atherosclerosis - Google Patents
Azetidinone derivatives for the treatment of atherosclerosisInfo
- Publication number
- IL122650A0 IL122650A0 IL12265096A IL12265096A IL122650A0 IL 122650 A0 IL122650 A0 IL 122650A0 IL 12265096 A IL12265096 A IL 12265096A IL 12265096 A IL12265096 A IL 12265096A IL 122650 A0 IL122650 A0 IL 122650A0
- Authority
- IL
- Israel
- Prior art keywords
- atherosclerosis
- treatment
- azetidinone derivatives
- azetidinone
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
- C07D205/085—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a nitrogen atom directly attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
- C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
- C07D205/095—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4 and with a nitrogen atom directly attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9513442.5A GB9513442D0 (en) | 1995-07-01 | 1995-07-01 | Novel compounds |
| GBGB9515056.1A GB9515056D0 (en) | 1995-07-22 | 1995-07-22 | Novel compounds |
| GBGB9515206.2A GB9515206D0 (en) | 1995-07-25 | 1995-07-25 | Novel compounds |
| GBGB9516985.0A GB9516985D0 (en) | 1995-08-18 | 1995-08-18 | Novel compounds |
| GBGB9525132.8A GB9525132D0 (en) | 1995-12-08 | 1995-12-08 | Novel compounds |
| GBGB9608650.9A GB9608650D0 (en) | 1996-04-26 | 1996-04-26 | Novel compounds |
| GBGB9608651.7A GB9608651D0 (en) | 1996-04-26 | 1996-04-26 | Novel compounds |
| PCT/EP1996/002765 WO1997002242A1 (en) | 1995-07-01 | 1996-06-20 | Azetidinone derivatives for the treatment of atherosclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL122650A0 true IL122650A0 (en) | 1998-08-16 |
Family
ID=27562921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12265096A IL122650A0 (en) | 1995-07-01 | 1996-06-20 | Azetidinone derivatives for the treatment of atherosclerosis |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP0840725A1 (en) |
| JP (1) | JP2002515852A (en) |
| KR (1) | KR19990028630A (en) |
| CN (1) | CN1197452A (en) |
| AP (1) | AP728A (en) |
| AU (1) | AU708032B2 (en) |
| BG (1) | BG102214A (en) |
| BR (1) | BR9609445A (en) |
| CA (1) | CA2225627A1 (en) |
| CZ (1) | CZ422197A3 (en) |
| EA (1) | EA199800109A1 (en) |
| HU (1) | HUP9901153A3 (en) |
| IL (1) | IL122650A0 (en) |
| MA (1) | MA23922A1 (en) |
| MX (1) | MX9800186A (en) |
| NO (1) | NO976158L (en) |
| NZ (1) | NZ311684A (en) |
| OA (1) | OA10648A (en) |
| PE (1) | PE8998A1 (en) |
| PL (1) | PL324240A1 (en) |
| SK (1) | SK178497A3 (en) |
| TR (1) | TR199701762T1 (en) |
| WO (1) | WO1997002242A1 (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000502079A (en) * | 1995-12-08 | 2000-02-22 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | Monocyclic .BETA.-lactam derivatives for the treatment of atherosclerosis |
| GB9608649D0 (en) * | 1996-04-26 | 1996-07-03 | Smithkline Beecham Plc | Novel compounds |
| EP0915843A1 (en) * | 1996-04-26 | 1999-05-19 | Smithkline Beecham Plc | Azetidinone derivatives for the treatment of atheroscleroses |
| DE60139429D1 (en) * | 2000-02-16 | 2009-09-10 | Smithkline Beecham Plc | Pyrimidine-5-onderivatives as LDL-PLA2 inhibitors |
| GB0024808D0 (en) | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
| US8962633B2 (en) | 2007-05-11 | 2015-02-24 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
| CN101687009A (en) | 2007-05-11 | 2010-03-31 | 宾夕法尼亚大学理事会 | Methods of treatment of skin ulcers |
| EA200971050A1 (en) | 2007-05-11 | 2010-06-30 | Томас Джефферсон Юниверсити | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS |
| TW201307324A (en) | 2010-12-06 | 2013-02-16 | Glaxo Group Ltd | Compounds |
| EP2651403B1 (en) | 2010-12-17 | 2020-12-02 | Glaxo Group Limited | Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases |
| EP2725024A4 (en) | 2011-06-27 | 2014-12-03 | Shanghai Inst Materia Medica | Azole heterocyclic compound, preparation method, pharmaceutical composition and use |
| BR112014001665A2 (en) | 2011-07-27 | 2017-02-14 | Glaxo Group Ltd | 2,3-dihydroimidazo [1,2-c] pyrimidin-5 (1h) -one compounds used as lp-plaz inhibitors |
| TW201321382A (en) | 2011-07-27 | 2013-06-01 | Glaxo Group Ltd | Compounds |
| CA2899143A1 (en) | 2013-01-25 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | Bicyclic pyrimidone compounds as inhibitors of lp-pla2 |
| WO2014114248A1 (en) | 2013-01-25 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
| EP2948452B1 (en) | 2013-01-25 | 2017-08-09 | GlaxoSmithKline Intellectual Property Development Limited | 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors |
| WO2016012917A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
| WO2016012916A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
| CN112778331B (en) | 2019-11-09 | 2022-07-05 | 上海赛默罗生物科技有限公司 | Tricyclic dihydroimidazopyrimidinone derivatives, preparation method, pharmaceutical composition and application thereof |
| CN115304620A (en) | 2021-05-07 | 2022-11-08 | 上海赛默罗生物科技有限公司 | Pyrimidone derivatives, preparation method, pharmaceutical composition and application thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4680391A (en) * | 1983-12-01 | 1987-07-14 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
| NZ228600A (en) * | 1988-04-11 | 1992-02-25 | Merck & Co Inc | 1-(benzylaminocarbonyl)-4-phenoxy-azetidin-2-one derivatives |
| IL99658A0 (en) * | 1990-10-15 | 1992-08-18 | Merck & Co Inc | Substituted azetidinones and pharmaceutical compositions containing them |
| GB9421816D0 (en) * | 1994-10-29 | 1994-12-14 | Smithkline Beecham Plc | Novel compounds |
| SK80397A3 (en) * | 1994-12-22 | 1998-01-14 | Smithkline Beecham Plc | Substituted azetidin-2-ones, preparation method thereof, farmaceutical compositions and their use |
-
1996
- 1996-06-20 SK SK1784-97A patent/SK178497A3/en unknown
- 1996-06-20 BR BR9609445A patent/BR9609445A/en unknown
- 1996-06-20 CA CA002225627A patent/CA2225627A1/en not_active Abandoned
- 1996-06-20 PL PL96324240A patent/PL324240A1/en unknown
- 1996-06-20 NZ NZ311684A patent/NZ311684A/en unknown
- 1996-06-20 WO PCT/EP1996/002765 patent/WO1997002242A1/en not_active Application Discontinuation
- 1996-06-20 JP JP50477297A patent/JP2002515852A/en active Pending
- 1996-06-20 IL IL12265096A patent/IL122650A0/en unknown
- 1996-06-20 KR KR1019970709952A patent/KR19990028630A/en not_active Application Discontinuation
- 1996-06-20 CZ CZ974221A patent/CZ422197A3/en unknown
- 1996-06-20 EP EP96922030A patent/EP0840725A1/en not_active Withdrawn
- 1996-06-20 HU HU9901153A patent/HUP9901153A3/en unknown
- 1996-06-20 AU AU63050/96A patent/AU708032B2/en not_active Ceased
- 1996-06-20 TR TR97/01762T patent/TR199701762T1/en unknown
- 1996-06-20 EA EA199800109A patent/EA199800109A1/en unknown
- 1996-06-20 AP APAP/P/1997/001161A patent/AP728A/en active
- 1996-06-20 CN CN96196661A patent/CN1197452A/en active Pending
- 1996-06-28 PE PE1996000496A patent/PE8998A1/en not_active Application Discontinuation
- 1996-06-28 MA MA24298A patent/MA23922A1/en unknown
-
1997
- 1997-12-30 NO NO976158A patent/NO976158L/en unknown
- 1997-12-31 OA OA70172A patent/OA10648A/en unknown
-
1998
- 1998-01-07 MX MX9800186A patent/MX9800186A/en unknown
- 1998-01-28 BG BG102214A patent/BG102214A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AP9701161A0 (en) | 1998-01-31 |
| MX9800186A (en) | 1998-07-31 |
| EA199800109A1 (en) | 1998-10-29 |
| BG102214A (en) | 1998-08-31 |
| HUP9901153A3 (en) | 1999-11-29 |
| CN1197452A (en) | 1998-10-28 |
| SK178497A3 (en) | 1998-07-08 |
| NZ311684A (en) | 2000-04-28 |
| EP0840725A1 (en) | 1998-05-13 |
| WO1997002242A1 (en) | 1997-01-23 |
| TR199701762T1 (en) | 1998-05-21 |
| PE8998A1 (en) | 1998-03-20 |
| CZ422197A3 (en) | 1998-06-17 |
| AU708032B2 (en) | 1999-07-29 |
| NO976158L (en) | 1998-02-25 |
| OA10648A (en) | 2002-09-25 |
| JP2002515852A (en) | 2002-05-28 |
| KR19990028630A (en) | 1999-04-15 |
| BR9609445A (en) | 1999-04-06 |
| NO976158D0 (en) | 1997-12-30 |
| PL324240A1 (en) | 1998-05-11 |
| AP728A (en) | 1999-01-29 |
| HUP9901153A2 (en) | 1999-08-30 |
| AU6305096A (en) | 1997-02-05 |
| CA2225627A1 (en) | 1997-01-23 |
| MA23922A1 (en) | 1996-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA959100B (en) | Azetidinone derivatives for the treatment of atherosclerosis | |
| AU4389896A (en) | Substituted azetidin-2-ones for treatment of atherosclerosis | |
| GB2298440B (en) | Well treatment | |
| PL322277A1 (en) | Derivatives of pyrazol-4-ylobenzoyl | |
| AP9701161A0 (en) | Azetidinone derivatives for the treatment of atherosclerosis | |
| AU5750796A (en) | System for the treatment of insomnia | |
| GB2306473A8 (en) | Glucoxide derivatives | |
| AU4247593A (en) | Imidazoles for the treatment of atherosclerosis | |
| PL324451A1 (en) | Derivatives of diphenylmethylenepiperidine | |
| IL126696A0 (en) | Azetidinone derivatives for the treatment of atherosclerosis | |
| ZA969221B (en) | Indolealkyl derivatives of benzodioxanmethylamine. | |
| GB9519033D0 (en) | Treatment | |
| AU3473193A (en) | Treatment for atherosclerosis | |
| EP0754668A3 (en) | Fluorobenzylether derivatives | |
| GB9516349D0 (en) | Aza-anthracyclinone derivatives | |
| ZA965276B (en) | Carboxamide derivatives | |
| GR3036344T3 (en) | 4-mercapto-benzoylguanidine derivatives | |
| AU4941796A (en) | Use of moxonidine for the treatment of atherosclerosis | |
| EP0804205A4 (en) | 4-aza-19-norandrostane derivatives | |
| ZA981731B (en) | Use of a 7alpha-methyl-17alpha-ethynyl-estrane derivative for the treatment of atherosclerosis | |
| GB9708363D0 (en) | Imidazopyridedine derivatives | |
| ZA968320B (en) | Treatment of atherosclerosis | |
| GB9509286D0 (en) | Masonry treatment | |
| GB9511475D0 (en) | Taxane derivatives | |
| GB9505805D0 (en) | Taxane derivatives |